Inclisiran sodium Drug Asset Due Diligence Report 2026

This Inclisiran sodium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Inclisiran sodium can convert its siRNA profile and PCSK9 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Inclisiran sodium (query alias: inclisiran)
Modality / target	siRNA; PCSK9; PCSK9 inhibitors, RNAi
Highest global status	Approved
Originator	Alnylam Pharmaceuticals, Inc.
Active developers	Novartis Pharma AG, China Novartis Institutes for BioMedical Research Co., Ltd., Sandoz GmbH

The MCP disease footprint includes Homozygous familial hypercholesterolemia, Hypercholesterolemia, Primary Hyperlipidemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07684469	Phase 4	Not yet recruiting	300	Percent change in LDL-C from baseline at Day 60
NCT07610278	Phase 2	Recruiting	120	Percent change from baseline of PCSK9 levels
NCT07626281	Phase 1	Recruiting	120	Primary plasma PK parameters: Cmax

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Efficacy, Safety, Tolerability and Quality of Life of Ongoing Individually Optimized Lipid-lowering Therapy With or Without Inclisiran (KJX839) - a Randomized, Placebo-controlled, Double-blind Multicenter Phase IV Study in Participants With Hypercholesterolemia

Phase 4; n=1770; evaluation: not stated. Reported fields: Number of Participants Achieving Individual LDL-C Target (<55 mg/dL or <70 mg/dL) = 266 Participants ; Number of Participants Achieving Individual LDL-C Target (<55 mg/dL or <70 mg/dL): Odds Ratio (OR) = 12.09(95% CI, 9.59 - 15.24), P-Value = <0.0001; Number of Participants Achieving Individual LDL-C Target (<55 mg/dL or <70 mg/dL): Odds Ratio (OR) = 12.09(95% CI, 9.59 - 15.24), P-Value = <0.0001

Early and sustained LDL-C goal achievement with inclisiran in patients at high cardiovascular risk

Phase 4; n=1770; evaluation: Positive. Reported fields: LDL-C(90-day) = 31.0 % Met; LDL-C(90-day) = 84.9 % Met

A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono)

Phase 3; n=350; evaluation: not stated. Reported fields: LS Mean (Treatment Policy estimand)(Least Squares Mean) = 1.37 Percentage change from baseline (95% Confidence Interval, -3.07 to 5.80); -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Inclisiran sodium addresses Homozygous familial hypercholesterolemia, Hypercholesterolemia, Primary Hyperlipidemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—siRNA—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 7 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-08-13	Bluemtec to distribute Novartis Korea's Leqvio to neighborhood clinics	Approved	Financial terms not disclosed
2021-09-01	World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)	Approved	Financial terms not disclosed
2020-04-13	Blackstone and Alnylam Enter Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics	NDA/BLA	US$2,000.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO